Medicine Manufacturer Vietnam | Vinphaco Speaker Tour Dong Thap 2026 — Pediatric Asthma & Cardiogenic Shock

Medicine Manufacturer Vietnam — Vinphaco’s Largest Clinical Education Event of 2026 Reaches the Mekong Delta 

On July 3, 2026, Vinphaco delivered the largest single session of its 2026 Speaker Tour series at Dong Thap General Hospital — bringing nearly 500 healthcare professionals from across the Dong Thap region together with two of Vietnam’s most respected pediatric specialists for a full-day clinical update on pediatric asthma diagnosis and management, and cardiogenic shock in children. As a medicine manufacturer Vietnam whose active ingredient portfolio spans respiratory, cardiovascular, and critical care therapeutic categories, this event represents more than clinical education sponsorship — it is direct, accountable engagement with the clinical environment in which Vinphaco’s products are prescribed and administered. For further context on Vinphaco’s Vietnamese operations, visit vinphaco.vn. 

1. Nearly 500 Clinicians — The Scale That Defines a Serious Clinical Partnership 

The attendance of nearly 500 healthcare professionals at a single provincial hospital event is a meaningful number in any clinical education context. Across Vietnam’s provincial healthcare system, it represents a significant share of the specialist clinical capacity of an entire region — Dong Thap’s Intensive Care, Pediatrics, Respiratory Medicine, Cardiology, and Emergency Medicine departments represented in a single professional development event. 

The program was chaired by Senior Specialist II Dr. Nguyen Hoang Viet, Deputy Director of Dong Thap General Hospital — whose institutional endorsement as session chair reflects the priority that hospital leadership places on advancing pediatric clinical standards across the facility’s departments. For international partners evaluating a medicine manufacturer Vietnam relationship, the combination of national specialist speakers, provincial hospital leadership, and 500 attending clinicians in a single session signals the kind of healthcare system depth that distinguishes a genuine clinical partner from a supplier with a marketing budget. 

2. Featured Speakers — Vietnam’s Most Senior Pediatric Academic and Clinical Leaders 

The Vinphaco Speaker Tour Dong Thap 2026 brought two of Vietnam’s most distinguished pediatric specialists — both drawn from the combined academic and clinical leadership of Ho Chi Minh City University of Medicine and Pharmacy and Children’s Hospital No. 1 — to a Mekong Delta provincial clinical audience. 

Associate Professor Dr. Phan Huu Nguyet Diem — Former Deputy Head, Department of Pediatrics, Ho Chi Minh City University of Medicine and Pharmacy; Former Head, General Pediatric Internal Medicine, Children’s Hospital No. 1. With decades of combined pediatric academic training and clinical practice leadership at Vietnam’s largest pediatric referral center, Assoc. Prof. Phan Huu Nguyet Diem brought to Dong Thap the most current evidence-based updates on pediatric asthma diagnosis and treatment — a disease area where misdiagnosis rates remain significant at the provincial level and where updated clinical protocols can directly reduce unnecessary hospitalisation and improve long-term quality of life for affected children. 

Associate Professor Dr. Vu Minh Phuc — Former Head, Department of Pediatrics; Former Vice Dean, Faculty of Medicine, Ho Chi Minh City University of Medicine and Pharmacy; Former Head, Cardiology Department, Children’s Hospital No. 1. As one of Vietnam’s foremost pediatric cardiology authorities — with leadership experience spanning both academic curriculum development and the clinical management of complex pediatric cardiac cases — Assoc. Prof. Vu Minh Phuc delivered the most authoritative available update on cardiogenic shock recognition and management in pediatric patients, a time-critical emergency condition where provincial clinician preparedness directly determines survival outcomes. 

Senior Specialist II Dr. Bui Li Mong, MSc. — Head, Pediatrics Department, Dong Thap General Hospital. As the host institution’s own pediatric department head, Dr. Bui Li Mong ensured that the program’s clinical content was interpreted through the specific operational lens of Dong Thap General Hospital — where geographic, climatic, and socioeconomic factors create a pediatric disease profile that differs meaningfully from urban tertiary center experience and requires locally calibrated clinical judgment. 

3. Pediatric Asthma and Cardiogenic Shock — Clinical Priorities Across Vinphaco’s Export Markets 

The dual clinical focus of the Dong Thap session — pediatric asthma management and pediatric cardiogenic shock — maps directly onto disease burdens that are significant across Vinphaco’s 24-country export network spanning Asia, Africa, and Oceania. 

Pediatric asthma affects an estimated 10–12% of school-age children in Vietnam, with higher burden in the Mekong Delta due to seasonal agricultural burning, high ambient humidity, and limited indoor environment control. Globally, asthma is the most common chronic respiratory disease in children, affecting over 260 million people worldwide — with disproportionate burden in low-to-middle income countries across Southeast Asia, South Asia, and Sub-Saharan Africa where Vinphaco maintains active export supply relationships. The bronchodilator and respiratory support active ingredients in Vinphaco’s production portfolio are directly relevant to the treatment protocols discussed at the Dong Thap session. 

Pediatric cardiogenic shock, while less prevalent, carries high case fatality rates in settings where early recognition capability and rapid intervention resources are limited — conditions that characterise many of Vinphaco’s export markets across Central Asia, West Africa, and Pacific Oceania. The cardiovascular and critical care active ingredients in Vinphaco’s portfolio — including agents used in shock management protocols — are produced to the GMP-WHO standards that clinical environments managing these emergencies depend on. 

4. Vinphaco Speaker Tour 2026 — A National Program, Now Exceeding 1,000 Clinicians Reached 

The Dong Thap session marks a cumulative milestone in Vinphaco’s 2026 clinical engagement program. Across the Speaker Tour series and associated conference participation in June and early July 2026 alone, Vinphaco has now directly engaged with over 1,000 healthcare professionals spanning respiratory medicine, infection control, critical care, pediatrics, cardiology, surgery, and internal medicine — in northern, central, and southern Vietnam simultaneously. 

Bac Ninh — nearly 100 healthcare professionals, respiratory medicine, Speaker Tour format with National Lung Hospital specialists. Phu Yen — nearly 150 healthcare professionals, hospital infection control, co-organised with Phu Yen General Hospital and Vietnam’s national infection control leadership. Can Tho — nearly 300 clinicians at the national respiratory medicine conference, Mekong Delta focus. Dong Thap — nearly 500 healthcare professionals, pediatric asthma and cardiogenic shock, largest single VST session of the year. 

This is a structured national clinical education program — not a series of unconnected events. For international partners assessing a medicine manufacturer Vietnam supplier relationship, the consistency, scale, and specialist depth of this program across four months is the clearest available evidence of how deeply Vinphaco’s quality commitments are embedded in real clinical accountability. 

5. Clinical Accountability at Scale — What 1,000+ Clinicians Mean for International Partners 

A medicine manufacturer Vietnam whose products are being discussed, evaluated, and applied by over 1,000 specialist clinicians per quarter — including national association presidents, university department heads, and provincial hospital directors — is a manufacturer operating under continuous, expert-level quality accountability that no factory audit can fully replicate. 

The clinicians attending Vinphaco’s Speaker Tour sessions are the same professionals prescribing and administering the active ingredients that Vinphaco manufactures. Their presence at these events — and their continued engagement with Vinphaco’s clinical education program across multiple sessions and specialties — reflects a level of trust in product quality and clinical relevance that is earned through manufacturing consistency, not claimed through marketing. 

For international buyers, distributors, and pharmaceutical contract manufacturing partners, this clinical ecosystem integration is the most durable quality signal available: the validation of a manufacturer’s standards by the expert community that depends on them most directly. 

To discuss pharmaceutical contract manufacturing, pediatric and respiratory active ingredient supply, private label arrangements, or international distribution partnerships: vinphaco.net/contact | vinphaco.vn